Yixin Zhao

Yixin Zhao

Auto-generated profile, based on publicly available information

Yixin Zhao

Huashan Hospital, Fudan University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2025 in Neurology
Verified
Journal Article
Closed access
XLXin-Yi Li
Xin-Yi Li
GTGan Tang
Gan Tang
JLJiaying Lu
Jiaying Lu
YZYixin Zhao
Yixin Zhao
HLHuamei Lin
Huamei Lin
F(For The Progressive Supranuclear Palsy Neuroimage Initiative (Pspni)
For The Progressive Supranuclear Palsy Neuroimage Initiative (Pspni)
Rapid eye movement sleep behavior disorder (RBD) is increasingly recognized in patients with tauopathies, but its significance and underpinnings remain unclear. To address this gap, we investigated the prevalence of self-reported RBD in patients with progressive supranuclear palsy (PSP) and explored its clinical and imaging correlates using 18F-florzolotau PET imaging. We consecutively enrolled patients meeting the 2017 Movement Disorder Society clinical criteria for PSP at a Chinese tertiary hospital between May 2019 and March 2022. Patients underwent comprehensive clinical assessments and 18F-florzolotau PET to investigate tau deposition patterns. The presence of self-reported RBD was identified using the RBD Single-Question Screen, while its frequency was retrospectively collected from medical history. We examined 148 patients recruited in the ongoing Progressive Supranuclear Palsy Neuroimage Initiative cohort. Self-reported RBD was identified in 18.2% of the participants (27/148). Patients with PSP-Richardson syndrome and PSP-parkinsonism reported the highest frequencies of self-reported RBD (21.7% and 18.5%, respectively), compared with PSP-progressive gait freezing (9.7%). While age and sex were similar in patients with and without self-reported RBD, the former group exhibited greater disease severity, as indicated by higher PSP Rating Scale (PSPrs) scores (38.0 vs 27.0, effect size = 0.256, p = 0.002). Furthermore, patients with RBD had significantly higher 18F-florzolotau binding in the locus coeruleus (LC) (1.50 vs 1.38, effect size = 0.231, p = 0.003), which remained significant after false discovery rate correction (p = 0.042). The frequency of RBD was found to be correlated with tau pathology in the LC (n = 8, r = 0.752, p = 0.002). Notably, the presence of self-reported RBD symptoms mediated the relationship between LC tau pathology and PSPrs total scores (proportion-mediated = 2.09%, 95% CI 0.01%-10.00%, p = 0.044). Approximately one-fifth of patients with PSP reported RBD and exhibited more severe motor and nonmotor symptoms. The elevated 18F-florzolotau binding in the LC and its association with the presence of RBD symptoms underscore the critical role of tau pathology in disrupting sleep-regulating neural circuits. Future studies with larger sample sizes should incorporate polysomnography in patients with PSP with self-reported RBD to further elucidate this relationship.

5 January 2024 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MLMengmeng Li
Mengmeng Li
MWMeng Wang
Meng Wang
YZYixin Zhao
Yixin Zhao
RZRui Zhong
Rui Zhong
WCWanying Chen
Wanying Chen
MWMeng Wei
Meng Wei

28 May 2026 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
YZYixin Zhao
Yixin Zhao
HLHuamei Lin
Huamei Lin
XLXinyi Li
Xinyi Li
QSQi Shen
Qi Shen
JWJing Wang
Jing Wang
FLFengtao Liu
Fengtao Liu
Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder with different metabolic patterns in parkinsonian (MSA-P) and cerebellar (MSA-C) subtypes, but their longitudinal changes are not well understood. To characterize longitudinal changes of glucose metabolism and network connectivity in MSA using 18 F-FDG-PET for early diagnosis and disease progression tracking, we retrospectively analyzed 29 MSA patients (17 MSA-P, 12 MSA-C) and 28 healthy controls. Regional glucose uptake was assessed as standardized uptake value ratios (SUVR). We examined inter-regional connectivity via correlation analysis and modeled metabolic decline using nonlinear mixed-effects models. Clinical progression was measured using the Unified Multiple System Atrophy Rating Scale (UMSARS). MSA-P displayed progressive hypometabolism in the putamen, cerebellum, and frontal cortex, while MSA-C showed declines primarily in the cerebellum and frontal regions. Longitudinal modeling indicated a faster putaminal decline in MSA-P ( β = −0.015 ± 0.006) than in MSA-C ( β = 0 ± 0.011), whereas cerebellar metabolism declined over time in both groups with overlapping slopes in MSA-P ( β = −0.022 ± 0.006) and MSA-C ( β = −0.022 ± 0.011). Regional metabolic reductions correlated with UMSARS progression (putamen in MSA-P: r = −0.59, p < 0.001; cerebellum in MSA-C: r = −0.62, p < 0.001). Significant connectivity disruptions were noted in frontal, basal ganglia, and cerebellar-parietal circuits. Longitudinal FDG-PET reveals distinct metabolic decline patterns in MSA subtypes—putamen in MSA-P and cerebellum in MSA-C—linked to clinical severity. These findings may inform clinical practice and trial design, supporting the use of FDG-PET for biological staging, monitoring disease progression, and potentially evaluating treatment responses.

8 July 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
LFLu Feng
Lu Feng
WLWen Liu
Wen Liu
YZYi-Xin Zhao
Yi-Xin Zhao
KCKun-Wang Chan
Kun-Wang Chan
QSQi Shen
Qi Shen
FLFengtao Liu
Fengtao Liu
Background: Behavioral variant of frontotemporal dementia (bvFTD) often presents with parkinsonism. Our study aimed to characterize the dopaminergic deficit pattern in bvFTD-parkinsonism (bvFTD-P) using dopamine transporter (DAT) positron emission tomography (PET) and to assess its potential value in differentiating bvFTD-P from progressive supranuclear palsy (PSP), multiple system atrophy–parkinsonism (MSA-P), and Parkinson disease (PD). Methods: A total of 30 bvFTD-P patients underwent 11 C-CFT or 18 F-FP-CIT PET and were compared with 71 patients with PSP, 41 with MSA-P, 61 with PD, and 43 healthy controls (HC). DAT binding values in the caudate, anterior putamen, and posterior putamen, as well as caudate/anterior putamen (C/AP) and caudate/posterior putamen (C/PP) ratios, were analyzed with generalized linear models. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic accuracy of DAT binding values and ratios. Results: BvFTD-P patients exhibited significantly reduced DAT binding in the caudate, anterior putamen, and posterior putamen compared with HC (all P <0.01), with a caudate-predominant deficit pattern (lower C/AP and C/PP ratios), contrasting with the putamen-predominant loss observed in PSP, MSA-P, and PD. This caudate-predominant pattern was replicated in the independent 18 F-FP-CIT cohort. ROC analysis demonstrated that the C/PP ratio provided superior discriminatory performance between bvFTD-P and HC or other parkinsonian syndromes than absolute binding values. Furthermore, lateralization of striatal DAT reduction corresponded to the side of predominant motor symptoms. Conclusions: The caudate-predominant pattern of striatal dopaminergic deficit in bvFTD-P may serve as a useful imaging biomarker for differentiating it from PSP, MSA-P, and PD.